Communiqués Sartorius AG OTC Markets

Actions

SOAGY

US80385Q2084

Equipement et technologie médicale avancés

Marché Fermé - OTC Markets 21:55:39 25/09/2026			Varia. 5j.	Varia. 1 janv.
59,17 ^USD	-2,28%		+3,88%	+1,88%

22/09	Sartorius AG : Deutsche Bank optimiste sur le dossier	ZD
16/09	Sartorius Aktiengesellschaft et le National Institute for Bioprocessing Research and Training annoncent un partenariat : création d'un centre de formation dédié aux bioprocédés intensifiés et continus	CI

Communiqués

16/09	Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing	EQ
23/07	Sartorius maintains positive momentum and continues to grow profitably	EQ
23/06	Sartorius : and LFB BIOMANUFACTURING strengthen collaboration	PU
21/05	Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany	EQ
06/05	Sartorius completes placement of bond with a volume of 500 million euros	EQ
06/05	Sartorius AG: Dr. Alexandra Gatzemeyer, Acquisition of 5,203 ordinary shares as a share‑based compensation component upon fulfillment of the relevant contractual condition.	EQ
06/05	Sartorius AG: Dr. Alexandra Gatzemeyer, Acquisition of 4,268 preferrence shares as a share‑based compensation component upon fulfillment of the relevant contractual condition.	EQ
24/04	Sartorius AG Supervisory Board extends appointment of board member Florian Funck	EQ
23/04	Sartorius marks positive start to 2026: Considerable sales revenue growth and resilient profit margin	EQ
26/03	Sartorius AG Supervisory Board extends appointment of board member René Fáber	EQ
26/03	Sartorius AG - Resolutions of the Annual General Meeting	EQ
17/03	Sartorius sharpens strategy with biopharma focus and sets new mid-term growth targets	EQ
16/03	Sartorius launches next-generation platform to boost efficiency in cell therapy production	EQ
12/03	Sartorius AG: Dr. Lothar Ewald Kappich, buy	EQ
12/03	Sartorius AG: Dr. Lothar Ewald Kappich, buy	EQ
16/02	Sartorius sharpens climate targets and receives validation from Science Based Targets initiative	EQ
16/02	Sartorius : Conference Call FY\|2025 Presentation	PU
16/02	Sartorius releases Annual Report for 2025	EQ
13/02	Sartorius AG: Ebsworth GmbH, buy	EQ
06/02	The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share	EQ
03/02	Sartorius achieves considerable profitable growth in 2025 and maintains positive outlook	EQ
14/01	Sartorius expands bio-circular product offering for more sustainable bioprocesses	EQ
01/01	Sartorius : Code of Conduct \| Chinese	PU
17/12	Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
17/12	Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ